



Published in final edited form as:

J Med Chem. 2012 November 8; 55(21): 8979–8996. doi:10.1021/jm301079z.

Microtubule Stabilizing Agents as Potential Treatment for Alzheimer's Disease and Related Neurodegenerative Tauopathies

Carlo Ballatore^{a,b,*}, Kurt R. Brunden^b, Donna M. Huryn^a, John Q. Trojanowski^b, Virginia M.-Y. Lee^b, and Amos B. Smith III^{a,*}

^aDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, 231 South 34th St., Philadelphia, PA 19104-6323

^bCenter for Neurodegenerative Diseases Research and Institute on Aging, Perelman School of Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104-6323

Abstract

The microtubule (MT)-associated protein tau, which is highly expressed in the axons of neurons, is an endogenous MT-stabilizing agent that plays an important role in the axonal transport. Loss of MT-stabilizing tau function, caused by misfolding, hyperphosphorylation and sequestration of tau into insoluble aggregates, leads to axonal transport deficits with neuropathological consequences. Several *in vitro* and preclinical *in vivo* studies have shown that MT-stabilizing drugs can be utilized to compensate for the loss of tau function and to maintain/restore an effective axonal transport. These findings indicate that MT-stabilizing compounds hold considerable promise for the treatment of Alzheimer disease and related tauopathies. The present article provides a synopsis of the key findings demonstrating the therapeutic potential of MT-stabilizing drugs in the context of neurodegenerative tauopathies, as well as an overview of the different classes of MT-stabilizing compounds.

Microtubule (MT) dynamics, axonal transport and neurodegenerative tauopathies

Microtubules (MTs), essential constituents of the cytoskeleton in eukaryotic cells, are involved in a number of important structural and regulatory functions, including the maintenance of cell shape, intracellular transport machinery, as well as cell-growth and division. Structurally, MTs are hollow tubes of approximately 24 nm in diameter that result from the head-to-tail polymerization of α - and β -tubulin heterodimers (Figure 1).¹

MTs are highly dynamic structures that alternate between growing and shrinking phases.² Because of this dynamic nature, MTs can undergo relatively rapid turnover and form a variety of different arrays within cells. The presence of various tubulin isoforms, post-translational modifications, and interactions with MT-associated proteins (MAPs) play an important role in determining the morphology, stability, and, ultimately, the particular function of the MT lattice in different cell types.

In the axons of neurons, MTs form polarized linear arrays with the plus ends directed toward the synapses and the minus ends toward the cell body. Such an organization of axonal MTs

*Corresponding Author. Amos B. Smith, III, smithab@sas.upenn.edu; Tel: (215) 898-2440; Fax: (215) 898-5129; Carlo Ballatore, bcarlo@sas.upenn.edu; Tel: (215) 898-4891.

provides both structural support and directionality for the intracellular transport of proteins and vesicles to and from the cell-body and the synapses (Figure 2). This cytoskeletal structure, together with molecular motors such as kinesins and dyneins, form the axonal transport machinery, which is critical to the viability of neurons³ and notably, axonal transport defects are observed in several neurodegenerative diseases.⁴ In the case of tauopathies, which are a group of neurodegenerative diseases that include Alzheimer's disease (AD) and related forms of frontotemporal lobar degeneration (FTLD), axonal transport deficits are thought to arise at least in part from the misfolding and aggregation of the MT-associated protein (MAP) tau.⁵ These tau aggregates form intracellular filamentous inclusions, known as neurofibrillary tangles (NFTs) and neuropil threads, which, together with the senile plaques comprised of amyloid β ($A\beta$ peptides, constitute the characteristic lesions that are diagnostic of AD. Furthermore, the presence of tau aggregates in the absence of deposits of $A\beta$ peptides or other proteinaceous inclusions comprise the defining lesions of other tauopathies, such as Pick's disease, progressive supranuclear palsy (PSP) and corticobasal degeneration, which are the most common forms of FTLD.⁵

Tau is expressed particularly in the axons of neurons with the primary function to promote MT-stabilization.⁶ Under physiological conditions, the vast majority of tau molecules are bound to MTs. However, in neurons affected by tauopathies, tau becomes progressively disengaged from the axonal MTs, possibly due to hyperphosphorylation, which is known to reduce the binding affinity of this protein for the MTs.^{7, 8} An abnormal detachment of tau from the MTs is thought to alter the dynamics and organization of the axonal MTs, which in turn can trigger or exacerbate axonal transport defects.³ Furthermore, once detached from MTs and hyperphosphorylated, tau becomes considerably more prone to misfolding and aggregation.^{9, 10} This misfolded and/or aggregated tau can in turn recruit additional functional tau proteins into the aggregation cascade, contributing further to the destabilization of axonal MTs.¹¹ Thus, based on the relationship between tau pathology and the appearance of MT¹² and axonal transport deficits, a possible strategy for the treatment of AD and related tauopathies is to employ exogenous MT-stabilizing agents that could compensate for loss of tau maintenance of the appropriate organization and dynamics of the axonal MTs.¹³ Such an approach would hold the promise of restoring effective axonal transport in neurons affected by tauopathy and, as a result, prevent synaptic dysfunctions and neuron loss.^{13, 14}

Over the past several decades, several classes of MT-stabilizing natural products have been discovered (Table 1) with the majority of these having been extensively characterized as cancer therapeutics due to the essential role of MTs in cell division. In contrast, as shown in Table 1, a comprehensive evaluation of the different classes of natural products in the context of neurodegenerative tauopathies has not as yet been achieved. A critical challenge facing the development of CNS-directed MT-stabilizing therapies to treat tauopathies is identifying brain-penetrant compounds that would be effective at non-toxic doses. Indeed, the blood-brain barrier (BBB), which is equipped with relatively impermeable intercellular tight junctions, as well as with active transporters such as the P-glycoprotein (Pgp),¹⁵ is known to be a remarkable obstacle in the development of any CNS-directed therapy.¹⁶ It is estimated that <2% of all potential drug candidates can permeate across the BBB.¹⁷ In addition, MT-stabilizing drugs, which are routinely used in cancer chemotherapy, are known to cause a number of debilitating side-effects, which are directly linked to the MT-stabilizing properties of these compounds, and include neutropenia¹⁸ and peripheral neuropathy.¹⁹ Thus, even if brainpenetration issues were solved, long-term treatment of tauopathy patients with this class of therapeutics might be difficult due to dose-limiting toxicities. Despite these important challenges, different lines of research have validated the potential utility of MT-stabilization as a therapeutic approach to treat tauopathies. *In vitro*, MT-stabilizing agents have been found to protect cultured neurons against tau-^{20, 21} and $A\beta$ -

mediated^{22–24} neurotoxicity. *In vivo*, the first demonstration of the therapeutic potential of this type of compounds was reported in 2005,²⁵ when paclitaxel treatment was found to restore fast axonal transport (FAT) and increase MT density in L5 axons that project from spinal motor neurons to lower limb muscles of T44 tau transgenic (Tg) mice affected by spinal cord tau pathology. Importantly, paclitaxel treatment produced an improvement in the motor weakness phenotype of these Tg mice due to uptake at neuromuscular junctions and retrograde transport.²⁵ However, paclitaxel does not cross the BBB and is thus unsuitable as a therapeutic candidate for human tauopathies where tau pathology is primarily in the brain. More recently, a series of studies from our laboratories^{26, 27} and subsequently from Bristol Myers Squibb²⁸ (BMS) provided further validation of this therapeutic approach using the brain-penetrant MT-stabilizing agent, epothilone D, to prevent and ameliorate disease in other lines of Tg mouse models with tau pathology in the brain that resembles that observed in tauopathy patients. In our studies, administration of low weekly doses of epothilone D by intraperitoneal (IP) injections into PS19 mice, which have NFT-like inclusions in the brain,²⁹ produced normalization of MT density, restoration of FAT, reduction in axonal dystrophy and decrease in neuronal pathology and death, with consequent improvement in cognitive performance.^{26, 27} Notably, these effects were seen both in preventative and interventional studies in which epothilone D was administered to PS19 mice either before or after the onset of tau pathology. Similar outcomes on neuropathology and cognition were observed in the BMS studies in which epothilone D was administered to rTg4510 and 3X tau Tg mice.²⁸

One important observation that was made in both the paclitaxel²⁵ and epothilone D *in vivo* studies^{26, 28} is that the dose-response curves appeared to be U-shaped, with relatively low doses of the compounds (*e.g.*, 100 times below the cumulative cancer chemotherapeutic dose, in the case of epothilone D^{26–28}) being most efficacious. This result indicates that low doses of MT-stabilizing agents may be both necessary and sufficient to restore the dynamics of axonal MTs and normalize FAT to physiological levels, and thus produce optimal therapeutic effects. Over-stabilization of MTs on the other hand may in fact be counter-productive and could be accompanied by side-effects such as peripheral neuropathy. Thus, an important outcome of the sustained low dose treatments with MT-stabilizing drugs is that Tg animals did not show signs of toxicities,^{26–28} including peripheral neuropathy and neutropenia.

Collectively, these findings indicate that brain-penetrant MT-stabilizing agents may be useful for the treatment of AD and related FTLT tauopathies. Pleasingly, BMS has recently initiated a Phase Ib clinical trial in which epothilone D is being evaluated in AD patients.³⁰ Moreover, since ~80% of Parkinson's disease (PD) patients develop dementia (PDD) by ~10 years after onset of PD, and AD-like tau pathology is associated with cognitive impairment in PDD, MT-stabilizing agents could be of therapeutic benefit to PDD patients.³¹

The highly promising results obtained from the epothilone D studies in our tau Tg animal models raise the possibility that other MT-stabilizing agents may be identified as alternative and potentially improved clinical candidates. As summarized in Table 1, although a growing number of MT-stabilizing natural products continue to be discovered, to date, only few selected compounds have been characterized as potential candidates for the treatment of neurodegenerative diseases. In the sections below, we provide an overview of the different classes of MT-stabilizing agents, including natural products as well as fully synthetic compounds, with a particular focus on those that might be useful to treat AD and other tauopathies.

MT-Stabilizing Natural Products and Analogues Thereof

Taxanes

Paclitaxel (Taxol[®], **1**, Figure 3), which was isolated in the 1960s from the stem bark of the western yew, *Taxus brevifolia*,³⁹ as well as from other species of the *Taxus* genus, was found to exhibit potent antitumor properties. The structure of paclitaxel was reported in 1971,⁴⁰ but the MT-stabilizing properties of this compound remained unknown until 1979, when the Horwitz laboratory in pioneering studies demonstrated that paclitaxel is able to promote MT-assembly *in vitro*.⁴¹ Paclitaxel binds to the lumen (*i.e.*, the inside) of the MT at a binding site found in the β -tubulin subunit,⁴² although an initial binding of this compound to the outer wall of the MT has been proposed, which may precede the translocation of this drug into the lumen of the MT.^{43, 44} The luminal binding site, which is commonly referred to as the *taxane* binding site, is also targeted by the MT-binding repeats of tau,⁴⁵ and paclitaxel is found to displace tau from MTs.⁴⁶ The binding of paclitaxel within the taxane site in β -tubulin is believed to promote MT-stabilization by inducing conformational changes of the M-loop of β -tubulin that result in more stable lateral interactions between adjacent protofilaments.⁴⁷

Because of the potent anti-mitotic properties, paclitaxel has been widely used for the treatment of cancer.⁴⁸ Much of the interest surrounding the MT-stabilizing class of therapeutics is arguably due to the success of paclitaxel and the closely related analogue, docetaxel (Taxotere[®], **2**, Figure 3) in cancer chemotherapy.⁴⁹ Although paclitaxel could be obtained only in limited quantities from the bark of *Taxus brevifolia*, the issue of supply was elegantly solved by semi-synthesis from more readily available 10-deacetylbaccatin III (**3**, Figure 3).^{50, 51} Among the various reported tactics to obtain paclitaxel from **3** (reviewed by Kingston *et al.*⁵²), the Ojima-Holton β -lactam strategy for the coupling of the phenylisoserine side-chain proved most effective.⁵³⁻⁵⁶ In addition to these semi-synthetic approaches, biotechnological methods of taxane production proved very effective.⁵⁷

Paclitaxel was the first MT-stabilizing agent to be investigated in an animal model of neurodegenerative tauopathies, the T44 tau Tg mouse, which exhibits tau pathology in spinal motor neurons that project outside the BBB to innervate striated muscles where there is no BBB equivalent.²⁵ However, the lack of brain penetration of paclitaxel precluded further investigations of this compound in mouse models of tauopathies that, unlike T44 tau Tg mice, more closely resemble human tauopathies with tau pathology in the brain.³⁶ The limited ability of paclitaxel and docetaxel to diffuse across the BBB is believed to be caused at least in part by the Pgp efflux pump,^{58, 59} which is highly expressed in the BBB.⁶⁰ Thus, taxane analogues capable of overcoming Pgp-mediated transport may result in improved brain penetration. Several examples of compounds of this type have been reported, which include: (a) weak Pgp-substrates, such as cabazitaxel³² (**6**, Figure 3), an FDA approved semisynthetic taxane that can saturate the active transporter;⁶¹ (b) taxoids that are also Pgp-inhibitors,⁶²⁻⁶⁴ such as SB-T-1213,⁶⁵ SB-T-1214⁶⁶ and IDN-5109⁶⁷ (**4**, **5**, and **6** respectively, Figure 3); and (c) taxoids that are devoid of Pgp-interactions, such as TX-67^{34, 68} (**8**, Figure 3). Among these Pgp-insensitive taxanes, **6** was found to exhibit greater brain-penetration than paclitaxel.³³ Furthermore, pharmacokinetic (PK) studies with **7** revealed that drug exposure in the brain could be significantly enhanced by administering the compound via rapid infusions that resulted in plasma drug levels that are above the threshold needed to saturate Pgp.⁶¹ Other examples of taxanes capable of circumventing Pgp-mediated efflux are orally active BMS- 275183^{69, 70} (**9**, Figure 3) and milataxel,^{71, 72} also known as MAC-321 (**10**, Figure 3).

In addition to these semisynthetic taxanes, promising results have been reported with brain targeted delivery approaches. An example of this strategy is the paclitaxel-peptide

conjugate, GRN1005³⁵ (**11**, Figure 3), a Pgp-insensitive prodrug that exploits the low density lipoprotein receptor-related protein 1 (LRP-1),⁷³ which is highly expressed in the BBB, to deliver paclitaxel into the brain via receptor-mediated uptake. Compound **11** was recently reported to be active in patients with advanced solid tumors with brain metastases.⁷⁴

The epothilones

Epothilone A and B (**12** and **13**, respectively, Figure 4), originally discovered by Hofle and Reichenbach as antifungal agents produced by the soil bacterium *Sorangium cellulosus*,⁷⁵ were later found by scientists at Merck to promote MT-assembly.⁷⁶ The same studies revealed that the epothilones compete with paclitaxel for the taxane binding site on β -tubulin, suggesting that this class of compounds may act on MTs in a taxol-like manner.⁷⁶ This observation led to the hypothesis that epothilones, taxanes, as well as other classes of MT-stabilizing natural products, may share a similar pharmacophore.⁷⁷ NMR⁷⁸ and computational studies⁷⁹ supported this common pharmacophore model, however, an evaluation by electron crystallography of the complex of epothilone A with tubulin polymerized in zinc-stabilized sheets demonstrated that epothilone A and paclitaxel interact in substantially different ways within the same binding pocket in β -tubulin.⁸⁰ Such differences in the binding modes provide a possible explanation as to why the epothilones, but not paclitaxel, retain generally high levels of anti-mitotic activity in cell-lines that are resistant to taxanes due to point mutations in the β -tubulin subunit.⁸¹ An additional distinctive feature of many of the epothilones is that these compounds, unlike paclitaxel and docetaxel, are active against cell lines with multi-drug resistance (MDR) caused by the overexpression of Pgp.

In addition to epothilone A and B, several other naturally occurring congeners have been isolated as minor components of fermentation of myxobacteria (**14–19**, Figure 4 A).⁸² Among these, epothilone D (**17**, Figure 4 A) exhibited a number of promising properties, including a greater therapeutic index as a chemotherapeutic agent, compared to **13**.⁸³ Clinical trials with this compound, however, were halted due to severe side-effects, which included CNS toxicities.⁸⁴ These CNS side effects are possibly the earliest evidence that **17** is a brain-penetrant compound, and reports from the patent literature indicated that this is indeed the case.⁸⁵ Furthermore, in 2006 **17** was reported to be effective in an animal model of schizophrenia, the STOP-null mouse model, which both lacks a MAP known as STOP (Stable Tubule Only Polypeptide) and exhibits cytoskeletal defects in CNS neurons.⁸⁶ The selection of **17** as preferred candidate compound for efficacy studies in tau Tg animals followed a comparative study in which selected taxanes and epothilone D congeners, including deoxy-epothilone F⁸⁷ and fludelone⁸⁸ (**19** and **20**, respectively, Figure 4), were evaluated for their ability to diffuse across cellular membranes *in vitro* and enter the brain *in vivo*. In addition, these compounds were tested for their ability to elicit MT-stabilization in the CNS of normal mice, as determined by the elevation in acetylated α -tubulin (AcTub), which is known to be a marker of stable MTs.^{89, 90} Interestingly, PK studies revealed that significant concentrations of these epothilones in the brain were achieved.³⁶ Furthermore, these studies showed that **17** exhibits a considerably longer half-life in the brain than in plasma. Similar PK properties have been described for **13**.³⁸ The ability of **17** to be retained selectively in the brain for relatively prolonged periods of time permitted infrequent (*i.e.*, weekly) administration of the compound in efficacy studies and likely reduced the potential for systemic toxicities in tau Tg mice.^{26, 27}

After the first total syntheses of **12** by the groups of Danishefsky,⁹¹ Nicolaou⁹² and Schinzer⁹³ between 1996–97, several synthetic strategies for the efficient synthesis of epothilone analogues have been developed (for comprehensive overview, see Altmann *et*

*al.*⁹⁴ and references therein). Collectively, these studies enabled the synthesis and evaluation of several hundred analogues. Among these, the epothilone lactam, ixabepilone (Ixempra[®], **24**, Figure 4 B), was the first epothilone to receive FDA approval for the treatment of metastatic breast cancer.⁹⁵ Other synthetic epothilones in clinical development include sagopilone (**25**, Figure 4 B),⁹⁶ which is characterized by the presence of the benzimidazole side-chain. Compound **25** was found to be more potent *in vitro* than **13**, as well as highly effective in mouse tumor xenograft models.^{96, 97} Notably, this compound has been found to be brain-penetrant.³⁷

Discodermolide

(+)-Discodermolide (**26**, Figure 5), a cytotoxic polyketide isolated by Gunasekera and co-workers from the deep-water Caribbean sponge *Discodermia dissoluta*,⁹⁸ was initially reported to be an immunosuppressant agent.^{99, 100} The MT-stabilizing properties of this compound were discovered in 1996,^{101, 102} when it was found that **26** is even more potent than paclitaxel in promoting the nucleation phase of tubulin-assembly. Further studies revealed that discodermolide, unlike paclitaxel, retains potent anti-mitotic activity against Pgp-overexpressing cancer cell lines.¹⁰³ Mechanistically, **26** was found to compete with paclitaxel for the taxane binding site on β -tubulin,^{102, 103} and photoaffinity labeling experiments by Horwitz, Smith and co-workers confirmed that the discodermolide binding site is in close proximity with the taxane site.¹⁰⁴ Interestingly, the bio-active conformation of **26** is believed to be U-shaped, where the C19 side chain comes close to the lactone moiety.¹⁰⁵ Overlays of this folded conformation of **26** and the bio-active conformation of paclitaxel highlight the similarities between the two 3D structures, supporting the possibility that both compounds adhere to a common pharmacophore.¹⁰⁵ However, unlike paclitaxel, tubulin-bound discodermolide is thought to interact with the N-terminal H1-S2 loop¹⁰⁶ and not with the M-loop, which is believed to be a key mediator of paclitaxel induced MT-stabilization.⁴⁷ This observation suggests that the MT-stabilizing effects of paclitaxel and discodermolide may be complementary,¹⁰⁶ thus providing an explanation for the observed synergistic effects of **26** and paclitaxel both *in vitro* and *in vivo*.^{107–109} Notably, **26** is the only example among the taxane site MT-stabilizing agents that shows synergy with paclitaxel.

The first total synthesis of discodermolide was reported by the Schreiber laboratory, which reported the synthesis of the natural product¹¹⁰ and, prior to that, the synthesis of the unnatural (–) antipode.¹¹¹ Several other syntheses of **26** have been reported (reviewed by Smith and Freeze¹¹²). Notably, the gram-scale synthesis devised by Smith and co-workers,^{113, 114} combined with Paterson's first generation endgame,¹¹⁵ was licensed to Novartis to permit the synthesis of 60 g of material needed to conduct a Phase I clinical trial.¹¹⁶ In addition to discodermolide, these synthetic efforts produced numerous analogues, including discodermolide-dictyostatin¹¹⁷ and discodermolide-paclitaxel¹¹⁸ hybrid structures. Interestingly, structural changes that impede the active U-shaped conformation proved to be highly detrimental to the biological activity. On the other hand, relatively substantial structural simplifications that maintain the characteristic folded conformation of **26** produced several interesting analogues (*e.g.*, **27**, Figure 5) with biological activities comparable to the parent compound.^{119, 120}

Dictyostatin

(–)-Dictyostatin (**28**, Figure 6), which was first isolated from a Maldives marine sponge *Spongia* sp. by Pettit and co-workers,¹²¹ was found to be highly potent against a variety of human cancer cell lines with a GI₅₀ in the 50 pM to 1 nM range. The MT-stabilizing properties of this compound were reported by the Harbor Branch Oceanographic Institute.¹²² The same studies also demonstrated that **28** is active against paclitaxel-resistant

cell lines that overexpress Pgp. Competition studies revealed that **28** binds to the taxane binding site.¹²³ Interestingly, the configurational assignment for dictyostatin is fully consistent with a common biogenesis for the structurally related, but open-chain, discodermolide. Indeed there is an exact configurational match of the C19-C26 and C6-C14 region of **28** with those at C17-C24 and C4-C12 of discodermolide, respectively. Moreover, it has been shown that the preferred conformation for **28** in solution closely resembles the conformation that was determined for discodermolide both in the solid state and in solution,¹²⁴ strongly suggesting that dictyostatin and discodermolide interact in a similar fashion with the taxane binding site on β -tubulin.^{125, 126}

The first total syntheses of (–)-dictyostatin were reported concurrently by the laboratories of Paterson¹²⁷ and Curran.¹²⁸ Other approaches to the natural product were later reported.^{129–131} Dictyostatin currently represents a promising antimitotic natural product lead for development in cancer chemotherapy. To date, the ability of this compound and/or related analogues to gain access to the CNS have not been reported.

Eleutherobin, sarcodyctins and related eleuthesides

Eleutherobin^{132, 133} (**29**, Figure 7) and sarcodyctins^{134, 135} (**30–33** Figure 7) are structurally related, coral-derived anti-mitotic agents isolated from *Eleutherobia* sp. and *Sarcodictyon roseum*, respectively. The abilities of these eleuthesides to promote MT-stabilization were described by Long *et al.*¹³³ (eleutherobin) and Ciomei *et al.*¹³⁶ (sarcodyctins). Competition binding studies revealed that these MT-stabilizing agents interact with β -tubulin at the taxane binding site.^{133, 137} Like paclitaxel, **29** was found to be a substrates for the Pgp.¹³³ The carbohydrate moiety of this compound is thought to be important for the eleutherobin-Pgp interaction, as indicated by the observation that analogues lacking this fragment,¹³⁸ such as SKBII.294 and SKBII.296 (**34** and **35**, respectively, Figure 7), did not appear to be sensitive to Pgp-mediated efflux.¹³⁸

Total syntheses of eleutherobin and sarcodyctins have been reported by the Nicolaou^{139–142} and Danishefsky laboratories.^{143–145} To date, no studies describing the evaluation of these compounds in either cell or animal models of neurodegenerative tauopathy have appeared.

Laulimalide

Laulimalide and the rearrangement product, isolaulimalide, (**36** and **37**, respectively, Figure 8) were isolated from marine sponges collected in Indonesia,¹⁴⁶ Vanatau,¹⁴⁷ and the island of Okinawa.¹⁴⁸ These compounds were described as cytotoxic agents; however, their mode of action was unknown until 1999, when Mooberry and co-workers reported that these compounds exhibit taxol-like MT-stabilizing properties.¹⁴⁹ In addition, the same studies demonstrated that **36** retains strong anti-mitotic activity against cancer cell-lines overexpressing Pgp.^{149, 150} Interestingly, competition studies with radiolabeled or fluorescently-labeled paclitaxel revealed that **36** does not compete for the taxane binding site.¹⁵⁰ Furthermore, consistent with this observation, **36** was found to be active against cell lines with β -tubulin mutations¹⁵¹ that cause resistance to both taxanes and epothilones.¹⁵⁰ In addition, synergistic effects of laulimalide with taxane drugs have been reported.¹⁵² Taken together, these results clearly indicate the existence of a distinct tubulin binding site for this compound. Recent studies revealed that **36** binds to the exterior of the MT on β -tubulin.¹⁵³

Because of these promising biological activities, and because of the limited natural supply, laulimalide became an attractive synthetic target. The first total synthesis of **36** was reported by Ghosh and co-workers.¹⁵⁴ Several other synthetic approaches, reviewed by Mulzer and Ohler,¹⁵⁵ have been developed. Notably, scientists at the Eisai Research Institute were able to synthesize sufficient quantities of laulimalide to enable *in vivo* efficacy studies.¹⁵⁶

Somewhat surprisingly, despite the promising *in vitro* anticancer activity, as well as PK properties, **36** did not produce a statistically significant tumor growth inhibition. The reasons for the lack of *in vivo* anticancer effects of laulimalide remain unclear but may be explained, at least in part, by the relatively high mitotic block reversibility ratio observed for this compound. A high reversibility of the anti-mitotic effect would imply that, *in vivo*, cancer cells exposed to laulimalide may resume mitosis soon after the circulating drug levels becomes sufficiently low.¹⁵⁷ Furthermore, this lack of *in vivo* anticancer activity was accompanied by severe toxicities indicating that **36** may not be a viable candidate for cancer chemotherapy.¹⁵⁷ However, subsequent studies in a different animal model demonstrated a significant inhibition of tumor growth.¹⁵⁸

Peloruside A

Isolated in New Zealand from the marine sponge, *Mycale hentscheli*, peloruside A (**38**, Figure 9) was identified as a potent cytotoxic agent with paclitaxel like activities.^{159, 160} In addition to the anti-mitotic activity, this natural product was found not to be affected by the overexpression of Pgp or by tubulin mutations that are known to affect the activity of paclitaxel.¹⁶¹ Competition binding experiments revealed that **38** does not bind to the taxane site in β -tubulin, while the observation that laulimalide can displace **38** clearly suggests that these two compounds may have overlapping binding sites.^{161, 162} In line with these results, **38** did not show synergistic effects with laulimalide, but like the latter, it was found to synergize with other taxane site drugs in both polymerizing purified tubulin¹⁵² and cellular activity.¹⁶³

The first total synthesis of peloruside A was reported in 2003 by De Brandander and co-workers.¹⁶⁴ Several other approaches to this natural product were later developed.^{165–171} In addition to **38**, other naturally occurring congeners have been isolated,^{172, 173} including peloruside B (**39**, Figure 9), which exhibits similar MT-stabilizing and biological activities as **38**.¹⁷²

Recent studies have shown that **38** protects cultured neurons against okadaic acid-induced tau phosphorylation.²¹ These results suggest that in addition to the epothilones, other MT-stabilizing agents, including those that do not target the taxane binding site on β -tubulin, such as peloruside and laulimalide, may be considered potential candidates for the treatment of tauopathies. However, there are presently no reports on the brain-penetration of **38**.²¹

Cyclostreptin

(–)-Cyclostreptin (**40**, Figure 10), a bacterial natural product also known as WS9885B and FR182877, was originally identified as a compound with paclitaxel-like biological activities using a cell-based screen for novel antimetabolic agents.^{174, 175} Structurally, **40** is characterized by an unusual ring system featuring a constrained α , β -unsaturated lactone. The natural product was initially assigned the opposite configuration.¹⁷⁶ Total syntheses of both (+) and (–)-cyclostreptin, as reported by the laboratories of Sorensen^{177, 178} and Evans,¹⁷⁹ confirmed the (–)-enantiomer to be the natural product.

Cytotoxicity studies revealed that **40**, although ~10 times less potent than paclitaxel in taxol-sensitive cell-lines, is considerably more effective than paclitaxel against Pgp-overexpressing cell-lines.¹⁸⁰ Furthermore, these studies demonstrated that **40** is not affected by tubulin mutations that are known to cause resistance to both paclitaxel and epothilone A.¹⁸⁰ Interestingly, whereas cyclostreptin was found to be an effective competitive inhibitor of the binding of paclitaxel to MTs, significant differences were observed in the MT-stabilizing properties of these two compounds. While cyclostreptin-treated MTs are more stable to depolymerizing conditions than those resulting from paclitaxel treatment,

cyclostreptin-induced MT-stabilization requires the presence of MAPs and GTP, which are not necessary for paclitaxel-induced MT-assembly.¹⁸⁰ Subsequent studies revealed that **40** interacts covalently with specific amino acid residues of β -tubulin in both MTs and tubulin dimers. These residues are Asn228, which resides in the proximity of the taxane binding site, and Thr220 at the outer surface of a pore⁴³ in the MT wall.¹⁸¹ Computational studies suggested that the covalent attachment of **40** to Thr220 may prevent the diffusion of paclitaxel and other taxane-binding drugs across the MT pore, into the taxane binding site.¹⁸² This model provides an explanation as to why **40** can prevent the binding of paclitaxel to β -tubulin despite the relatively weak tubulin polymerization properties compared to paclitaxel. Cyclostreptin is the first example of a MT-stabilizing agent found to interact irreversibly with tubulin. Similar mode of action has recently been reported for zampanolide¹⁸³ (*vide infra*). To date, there are no reports of **40** being evaluated in cell- and/or animal-models of tauopathies; thus, it is not clear yet whether the particular mode of action of cyclostreptin, which involves covalent modification of tubulin, may be effective in restoring axonal transport deficits in neurons affected by tauopathy.

Taccalonolides

Taccalonolides are steroidal natural products that were originally isolated in 1963 from the tubers of *Tacca leontopetaloides*.¹⁸⁴ The structure of these compounds was fully elucidated in 1987, when Chen and co-worker characterized taccalonolide A and B (**41** and **42**, respectively, Figure 11) from *Tacca plantaginea*.¹⁸⁵ Since then, several other members of the taccalonolide class have been discovered (*e.g.*, **43** and **44**, Figure 11).^{186–189} The MT-stabilizing properties of the taccalonolides were first recognized in 2003, when taccalonolide A and E were found to cause paclitaxel-like MT-bundling in dividing cells.¹⁹⁰ Furthermore, the taccalonolides were found to be poor substrates for the Pgp and exhibit only limited cross-resistance with paclitaxel.^{190, 191}

The mode of action of this class of natural products remains an active area of investigation. Studies with **41** and **42** revealed that the taccalonolides do not bind to either tubulin or MTs,¹⁹² and that the MT-stabilizing properties of these compounds is observed only in intact cells, but not in cell extracts or purified tubulin preparations.^{192, 193} Recent studies, however, reported the identification of considerably more potent MT-stabilizing members of the taccalonolide family, such as taccalonolide AF and AJ (**45** and **46**, respectively, Figure 11), that promote MT assembly from purified tubulin.¹⁸⁹ Further studies are needed to elucidate the mode of action of taccalonolides and evaluate the potential of taccalonolides in the context of neurodegenerative disorders. To date, there are no reports describing the total synthesis of taccalonolides.

Zampanolide and dactylolide

(–)-Zampanolide and (+)-dactylolide (**47** and **48**, respectively, Figure 12), are structurally-related natural products isolated, respectively, from *Fasciospongia rimosa*,¹⁹⁴ the same sponge found in the island of Okinawa that yielded laulimalide,¹⁴⁸ and from *Dactylospongia sp.*¹⁹⁵ These two compounds share the same highly unsaturated macrolactone core but with opposite absolute configuration. In addition, zampanolide features a characteristic *N*-acyl hemiaminal side chain. The total synthesis and assignment of absolute configuration of both antipodes of **47** and **48** were reported first by the Smith and then Hoye laboratories.^{196–205}

In 2009, **47** was reported to stabilize MTs in cells, and to promote the polymerization of purified tubulin in cell-free assays.²⁰⁶ The same studies revealed that **47** exhibits low nM IC₅₀ against several cell-lines, including those that overexpress the Pgp.²⁰⁶ Similar MT-stabilizing properties have been described for **48**,²⁰⁷ although this compound was found to be considerably less cytotoxic than **47**, with IC₅₀ values in the low RM range.¹⁹⁵

Competition binding studies revealed that **47** targets the taxane site and does not interfere with the binding of laulimalide with MTs.¹⁸³ Interestingly, these studies also revealed that the mode of action of **47** and **48**, like cyclostreptin, involves covalent modification of specific residues (Asn228 and His229) found in the taxane binding site. However, compared to cyclostreptin, **47** is a considerably more potent MT-stabilizing agent. As in the case of cyclostreptin, the therapeutic potential of **47** as a treatment for tauopathies may be limited due to the alkylating properties of this compound.

Ceratamines

Ceratamine A and B (**49** and **50**, respectively, Figure 13), originally isolated from marine sponge *Pseudoceratina* sp. collected in Papua New Guinea, are antimetabolic heterocyclic alkaloids characterized by an unusual imidazo[4,5-*d*]-azepine core.²⁰⁸

These compounds were found to promote the polymerization of purified tubulin in the absence of MAPs, although less potently than paclitaxel.²⁰⁹ Competition binding studies revealed that the ceratamines do not act as competitive inhibitors of paclitaxel binding.²⁰⁹

Interestingly, ceratamines are the only non-chiral examples among all MT-stabilizing natural products. Because of this, and because of the comparatively simpler structure, ceratamines are considered as promising lead compounds for cancer chemotherapy.²⁰⁹ Such attributes also suggest that compounds from this class may be identified as CNS-active candidates for the treatment of tauopathies. The syntheses of the natural products have been described by Coleman and co-workers,²¹⁰ with several analogues constructed and evaluated.^{211, 212} This effort resulted in the identification of selected derivatives (e.g., **51**, Figure 13) with improved antimetabolic and MT-stabilizing properties.²¹¹

Other naturally occurring compounds with reported MT-stabilizing properties

In addition to the different classes of natural products discussed above, a number of other naturally occurring compounds, or derivatives thereof, have been reported to exhibit MT-stabilizing properties (Figure 14). These include dicumarol (**52**),²¹³ jatrophanes (**53–55**),²¹⁴ tubercidin (**56**),²¹⁵ xanthophylls (e.g., lutein, **57**),²¹⁶ as well as the NAP peptide (**58**), also known as davunetide, which is a short peptide fragment (NAPVSIQ) derived from the activity-dependent neuroprotective protein (ADNP).²¹⁷ However, as reported by Buey and co-workers,¹⁹² who conducted a comparative study involving different classes of MT-stabilizing agents, the MT-stabilizing properties of most of these compounds (i.e., **52–55**, **57**) were not confirmed. Likewise, the NAP peptide, which has been found to be neuroprotective in many different animal models (reviewed by Gozes and co-workers^{218–220}) and is currently in Phase II/III clinical trials for AD and progressive supranuclear palsy (PSP), was reported to be a MT-stabilizing agent.^{221, 222} However recent studies indicate that this peptide may not directly impact MT-dynamics.²²³

Synthetic MT-stabilizing Agents

Although the vast majority of known MT-stabilizing agents are structurally complex natural products, progress has been made in the identification of small synthetic molecules with MT-stabilizing properties. These compounds, which include GS-164 (**59**), identified by scientists at Takeda Chemical Industries Ltd.,²²⁴ selected estradiol derivatives,²²⁵ such as **60**, and a derivative of thalidomide, 5HPP-33 (**61**),²²⁶ could be considered as potentially interesting leads for AD drug discovery programs (Figure 15).

Furthermore, screening programs directed at the discovery of antifungal agents identified multiple series of synthetic mono- and di-heterocyclic compounds with MT-stabilizing properties, including certain triazolopyrimidines, typified by cevipabulin²²⁷ (also known as

TTI-237, **62**, Figure 16A), as well as some structurally related phenylpyrimidines²²⁸ (Figure 16B), pyridopyridazines,²²⁹ pyridotriazines²³⁰ (Figure 16C) and pyridazines²³¹ (e.g., **63**, Figure 16D).

Although the vast majority of these synthetic MT-stabilizing agents have been investigated only as anti-fungal agents, in recent years there have been reports of compounds of this type being explored as potential anticancer drugs. Among these, **62** displayed excellent anti-cancer activities in several nude mouse tumor xenograft models.²²⁷ Moreover, **62** was found to exhibit excellent pharmaceutical properties, including oral bioavailability, metabolic stability, and water-solubility.²²⁷ Interestingly, the mechanism by which these heterocyclic compounds promote MT-stabilization appears to be distinct from that of other classes of MT-stabilizing natural products.^{232, 233} In fact, radioligand binding studies demonstrated that **62** does not compete for the taxane binding site on β -tubulin.²³² Instead, this compound appears to affect vinblastine binding to β -tubulin, although it is not clear yet whether this results from overlapping binding sites or a distinct allosteric cevipabulin site.²³² However, in sharp contrast to the mechanism of vinblastine, vincristine and other vinca alkaloids, which de-stabilize MTs, **62** and related congeners promote the polymerization of tubulin into MTs.^{232, 233} Cevipabulin is currently undergoing clinical trials as an anti-cancer agent.²³⁴ However, because of the MT-stabilizing ability, favorable physical-chemical properties and synthetic accessibility, **62** and/or related analogues may hold promise in the development of CNS-active MT-stabilizing therapies.

Concluding remarks

Over the past several years, remarkable progress has been made in the development of tau focused therapies from target identification towards clinical trials for AD and related FTL D tauopathies (see Lee *et al.*²³⁵). Among a growing number of potentially druggable targets that could abrogate tau-mediated neurodegeneration,²³⁶ counteracting the functional loss of tau with MT-stabilizing agents is one of the most biologically and pathologically well grounded. Thus, these agents appear to be amongst the most compelling as potential treatments for neurodegenerative tauopathies. The promising results obtained from the epothilone D studies in tau Tg animal models, summarized here, provide important validation of this therapeutic strategy and, notably, have resulted in the selection of epothilone D as a clinical candidate for the treatment of AD.³⁰

Acknowledgments

Financial support for this work has been provided by the NIH/NIA (Grant AG029213)

Abbreviations used

MT	microtubule
AD	Alzheimer's disease
PD	Parkinson's disease
CNS	central nervous system
FTLD	frontotemporal lobar degeneration
PSP	progressive supranuclear palsy
NFT	neurofibrillary tangle
BBB	blood-brain barrier

FAT	fast axonal transport
Pgp	P-glycoprotein
Tg	transgenic
MDR	multi-drug resistance
FDA	Food and Drug Administration
SAR	structure-activity relationship
B/P	brain to plasma ratio
PK	pharmacokinetic
PD	pharmacodynamic
BMS	Bristol-Myers Squibb
ADNP	activity dependent neuroprotective protein

References

- Desai A, Mitchison TJ. Microtubule polymerization dynamics. *Annu Rev Cell Dev Biol.* 1997; 13:83–117. [PubMed: 9442869]
- Mitchison T, Kirschner M. Dynamic instability of microtubule growth. *Nature.* 1984; 312:237–242. [PubMed: 6504138]
- Roy S, Zhang B, Lee VMY, Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. *Acta Neuropathol (Berl).* 2005; 109:5–13. [PubMed: 15645263]
- De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. *Annu Rev Neurosci.* 2008; 31:151–173. [PubMed: 18558852]
- Lee VMY, Goedert M, Trojanowski JQ. Neurodegenerative Tauopathies. *Annu Rev Neurosci.* 2001; 24:1121–1159. [PubMed: 11520930]
- Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. *Mol Biol Cell.* 1992; 3:1141–1154. [PubMed: 1421571]
- Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. *Neuron.* 1993; 11:153–163. [PubMed: 8393323]
- Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Rev.* 2000; 33:95–130. [PubMed: 10967355]
- Kuret J, Congdon Erin E, Li Guibin, Yin Haishan, Yu Xian, Zhong Q. Evaluating triggers and enhancers of tau fibrillization. *Micros Res Techniq.* 2005; 67:141–155.
- Kuret J, Chirita CN, Congdon EE, Kannanayakal T, Li G, Necula M, Yin H, Zhong Q. Pathways of tau fibrillization. *BBA-Mol Basis Dis.* 2005; 1739:167–178.
- Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nat Rev Neurosci.* 2007; 8:663–672. [PubMed: 17684513]
- Hempfen B, Brion JP. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. *J Neuropathol Exp Neurol.* 1996; 55:964–972. [PubMed: 8800092]
- Lee VMY, Daughenbaugh R, Trojanowski JQ. Microtubule stabilizing drugs for the treatment of Alzheimer's disease. *Neurobiol Aging.* 1994; 15 (Suppl 2):S87–89. [PubMed: 7700471]
- Trojanowski JQ, Smith AB, Huryn D, Lee VMY. Microtubule-stabilizing drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. *Expert Opin Pharmacother.* 2005; 6:683–686. [PubMed: 15934894]
- Tsuji A, Tamai I. Blood-brain barrier function of P-glycoprotein. *Adv Drug Del Rev.* 1997; 25:287–298.

16. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. *NeuroRx*. 2005; 2:3–14. [PubMed: 15717053]
17. Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated? *Drug Discov Today*. 2002; 7:5–7. [PubMed: 11790589]
18. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. *Nat Rev Clin Oncol*. 2010; 7:22–36. [PubMed: 19997076]
19. Lee J, Swain SM. Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents. *J Clin Oncol*. 2006; 24:1633–1642. [PubMed: 16575015]
20. Shemesh OA, Spira ME. Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimetabolic drug paclitaxel. *Neurobiol Dis*. 2011; 43:163–175. [PubMed: 21406229]
21. Das V, Miller JH. Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation. *Eur J Neurosci*. 2012; 35:1705–1717. [PubMed: 22594877]
22. Michaelis ML, Ranciat N, Chen Y, Bechtel M, Ragan R, Hepperle M, Liu Y, Georg G. Protection Against beta-Amyloid Toxicity in Primary Neurons by Paclitaxel (Taxol). *J Neurochem*. 1998; 70:1623–1627. [PubMed: 9523579]
23. Michaelis ML, Chen Y, Hill S, Reiff E, Georg G, Rice A, Audus K. Amyloid peptide toxicity and microtubule-stabilizing drugs. *J Mol Neurosci*. 2002; 19:101–105. [PubMed: 12212764]
24. Michaelis ML, Ansar S, Chen Y, Reiff ER, Seyb KI, Himes RH, Audus KL, Georg GL. {beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. *J Pharmacol Exp Ther*. 2005; 312:659–68. [PubMed: 15375176]
25. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VMY, Trojanowski JQ. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. *Proc Natl Acad Sci U S A*. 2005; 102:227–231. [PubMed: 15615853]
26. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C, Smith AB, Lee VM, Trojanowski JQ. Etoposide D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. *J Neurosci*. 2010; 30:13861–13866. [PubMed: 20943926]
27. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB, Lee VM, Brunden KR. The microtubule-stabilizing agent, etoposide d, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. *J Neurosci*. 2012; 32:3601–3611. [PubMed: 22423084]
28. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PYA, Husted KH, Cadelina GW, DeCarr LB, Yang L, Liu L, Fessler C, Protassio J, Riff T, Turner H, Janus CG, Sankaranarayanan S, Polson C, Meredith JE, Gray G, Hanna A, Olson RE, Kim SH, Vite GD, Lee FY, Albright CF. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. *J Neurosci*. 2012; 32:7137–7145. [PubMed: 22623658]
29. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VMY. Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. *Neuron*. 2007; 53:337–351. [PubMed: 17270732]
30. <http://clinicaltrials.gov/ct2/show/NCT01492374?term=BMS-241027&rank=1>.
31. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM-Y, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ. Neuropathologic substrates of Parkinson's disease dementia. *Ann Neurol*. 2012 in press.
32. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. *Nat Rev Drug Discov*. 2010; 9:677–678. [PubMed: 20811375]
33. Laccabue D, Tortoreto M, Veneroni S, Perego P, Scanziani E, Zucchetti M, Zaffaroni M, D'Incalci M, Bombardelli E, Zunino F, Pratesi G. A novel taxane active against an orthotopically growing human glioma xenograft. *Cancer*. 2001; 92:3085–3092. [PubMed: 11753988]

34. Rice A, Liu Y, Michaelis ML, Himes RH, Georg GI, Audus KL. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. *J Med Chem.* 2005; 48:832–838. [PubMed: 15689167]
35. Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R, Beliveau R, Castaigne JP. Antitumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. *Br J Pharmacol.* 2008; 155:185–197. [PubMed: 18574456]
36. Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, Hogan AM, Trojanowski JQ, Smith AB, Lee VM. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. *Pharmacol Res.* 2011; 63:341–351. [PubMed: 21163349]
37. Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, Hofmann B, Klar U. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. *Neuro Oncol.* 2009; 11:158–166. [PubMed: 18780814]
38. O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. *Cancer Chemother Pharmacol.* 2008; 62:1045–1054. [PubMed: 18301895]
39. Wall, ME.; Wani, MC. Paper No. M-006. 153rd National Meeting of the American Chemical Society; Miami Beach, Fla. 1967.
40. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J Am Chem Soc.* 1971; 93:2325–2327. [PubMed: 5553076]
41. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. *Nature.* 1979; 277:665–667. [PubMed: 423966]
42. Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KH. Structure of tubulin at 6.5 Å and location of the taxol-binding site. *Nature.* 1995; 375:424–427. [PubMed: 7760939]
43. Díaz JF, Barasoain I, Andreu JM. Fast Kinetics of Taxol Binding to Microtubules. *J Biol Chem.* 2003; 278:8407–8419. [PubMed: 12496245]
44. Barasoain I, Garcia-Carril AM, Matesanz R, Maccari G, Trigili C, Mori M, Shi JZ, Fang WS, Andreu JM, Botta M, Diaz JF. Probing the Pore Drug Binding Site of Microtubules with Fluorescent Taxanes: Evidence of Two Binding Poses. *Chem Biol.* 2010; 17:243–253. [PubMed: 20338516]
45. Amos LA. Microtubule structure and its stabilisation. *Org Biomol Chem.* 2004; 2:2153–2160. [PubMed: 15280946]
46. Samsonov A, Yu JZ, Rasenick M, Popov SV. Tau interaction with microtubules in vivo. *J Cell Sci.* 2004; 117:6129–6141. [PubMed: 15564376]
47. Amos LA, Lowe J. How Taxol stabilises microtubule structure. *Chem Biol.* 1999; 6:R65–9. [PubMed: 10074470]
48. Eisenhauer EA, Vermorken JB. The Taxoids: Comparative Clinical Pharmacology and Therapeutic Potential. *Drugs.* 1998; 55:5–30. [PubMed: 9463787]
49. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. *Nat Rev Cancer.* 2004; 4:253–265. [PubMed: 15057285]
50. Denis JN, Greene AE, Guenard D, Gueritte-Voegelein F, Mangatal L, Potier P. Highly efficient, practical approach to natural taxol. *J Am Chem Soc.* 1988; 110:5917–5919.
51. Guenard D, Gueritte-Voegelein F, Potier P. Taxol and taxotere: discovery, chemistry, and structure-activity relationships. *Acc Chem Res.* 1993; 26:160–167.
52. Kingston DG, Jagtap PG, Yuan H, Samala L. The chemistry of taxol and related taxoids. *Fortschr Chem Org Naturst.* 2002; 84:53–225. [PubMed: 12132389]
53. Ojima I. Recent Advances in the .beta.-Lactam Synthone Method. *Acc Chem Res.* 1995; 28:383–389.
54. Ojima I, Habus I, Zhao M, Zucco M, Park YH, Sun CM, Brigaud T. New and efficient approaches to the semisynthesis of taxol and its C-13 side chain analogs by means of β -lactam synthon method. *Tetrahedron.* 1992; 48:6985–7012.

55. Georg GI, Cheruvallath ZS, Himes RH, Mejillano MR, Burke CT. Synthesis of biologically active taxol analogs with modified phenylisoserine side chains. *J Med Chem.* 1992; 35:4230–4237. [PubMed: 1359143]
56. Holton, RA. Method for preparation of taxol using beta lactam. US005175315A. 1992.
57. Exposito O, Bonfill M, Moyano E, Onrubia M, Mirjalili MH, Cusido RM, Palazon J. Biotechnological production of taxol and related taxoids: current state and prospects. *Anticancer Agents Med Chem.* 2009; 9:109–121. [PubMed: 19149486]
58. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O. Increased Penetration of Paclitaxel into the Brain by Inhibition of P-Glycoprotein. *Clin Cancer Res.* 2003; 9:2849–2855. [PubMed: 12855665]
59. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. *J Clin Invest.* 2002; 110:1309–1318. [PubMed: 12417570]
60. Beaulieu E, Demeule M, Ghitescu L, Beliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. *Biochem J.* 1997; 326 (Pt 2): 539–544. [PubMed: 9291129]
61. Bouchet BP, Galmarini CM. Cabazitaxel, a new taxane with favorable properties. *Drugs Today (Barc).* 2010; 46:735–742. [PubMed: 21076710]
62. Ferlini C, Distefano M, Pignatelli F, Lin S, Riva A, Bombardelli E, Mancuso S, Ojima I, Scambia G. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. *Br J Cancer.* 2000; 83:1762–1768. [PubMed: 11104578]
63. Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. *J Natl Cancer Inst.* 2001; 93:1234–1245. [PubMed: 11504769]
64. Minderman H, Brooks TA, O’Loughlin KL, Ojima I, Bernacki RJ, Baer MR. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. *Cancer Chemother Pharmacol.* 2004; 53:363–369. [PubMed: 15060738]
65. Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. *J Med Chem.* 1996; 39:3889–3896. [PubMed: 8831755]
66. Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, Gallager D, Zhao X, Zanardi I, Xia S, Horwitz SB, Mallen-St Clair J, Guerriero JL, Bar-Sagi D, Veith JM, Pera P, Bernacki RJ. Design, synthesis, and biological evaluation of new-generation taxoids. *J Med Chem.* 2008; 51:3203–3221. [PubMed: 18465846]
67. Distefano M, Scambia G, Ferlini C, Gaggini C, De Vincenzo R, Riva A, Bombardelli E, Ojima I, Fattorossi A, Panici PB, Mancuso S. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaicatin III derivatives) on multidrug-resistance-positive human cancer cells. *Int J Cancer.* 1997; 72:844–850. [PubMed: 9311603]
68. Rice A, Michaelis M, Georg G, Liu Y, Turunen B, Audus K. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. *J Mol Neurosci.* 2003; 20:339–343. [PubMed: 14501017]
69. Mastalerz H, Cook D, Fairchild CR, Hansel S, Johnson W, Kadow JF, Long BH, Rose WC, Tarrant J, Wu MJ, Xue MQ, Zhang G, Zoeckler M, Vyas DM. The discovery of BMS-275183: an orally efficacious novel taxane. *Bioorg Med Chem.* 2003; 11:4315–4323. [PubMed: 13129567]
70. Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF. Preclinical pharmacology of BMS-275183; an orally active taxane. *Clin Cancer Res.* 2001; 7:2016–2021. [PubMed: 11448919]
71. Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, Greenberger LM. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. *Mol Cancer Ther.* 2003; 2:873–884.
72. Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. *Cancer Chemother Pharmacol.* 2007; 60:203–209. [PubMed: 17091249]

73. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, Castaigne JP, Beliveau R. Identification and design of peptides as a new drug delivery system for the brain. *J Pharmacol Exp Ther.* 2008; 324:1064–1072. [PubMed: 18156463]
74. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. *Mol Cancer Ther.* 2012; 11:308–316. [PubMed: 22203732]
75. Hofle, G.; Reichenbach, H. *Anticancer agents from natural products.* CRC Press LLC; Boca Raton, FL: 2005. *Anticancer agents from natural products*; p. 413-450.
76. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. *Cancer Res.* 1995; 55:2325–2333. [PubMed: 7757983]
77. Ojima I, Chakravarty S, Inoue T, Lin S, He L, Horwitz SB, Kuduk SD, Danishefsky SJ. A common pharmacophore for cytotoxic natural products that stabilize microtubules. *Proc Natl Acad Sci U S A.* 1999; 96:4256–4261. [PubMed: 10200249]
78. Reese M, Sanchez-Pedregal VM, Kubicek K, Meiler J, Blommers MJJ, Griesinger C, Carlomagno T. Structural Basis of the Activity of the Microtubule-Stabilizing Agent Epothilone A Studied by NMR Spectroscopy in Solution. *Angewandte Chemie.* 2007; 119:1896–1900.
79. Forli S, Manetti F, Altmann KH, Botta M. Evaluation of novel epothilone analogues by means of a common pharmacophore and a QSAR pseudoreceptor model for taxanes and epothilones. *ChemMedChem.* 2010; 5:35–40. [PubMed: 19904799]
80. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. *Science.* 2004; 305:866–9. [PubMed: 15297674]
81. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. *J Biol Chem.* 1997; 272:17118–17125. [PubMed: 9202030]
82. Hardt IH, Steinmetz H, Gerth K, Sasse F, Reichenbach H, Hofle G. New natural epothilones from *Sorangium cellulosum*, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies. *J Nat Prod.* 2001; 64:847–856. [PubMed: 11473410]
83. Kolman A. Epothilone D (Kosan/Roche). *Curr Opin Investig Drugs.* 2004; 5:657–667.
84. Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. *Invest New Drugs.* 2007; 25:565–570. [PubMed: 17618407]
85. Lichtner, RM.; Rotgeri, A.; Klar, U.; Hoffmann, J.; Buchmann, B.; Schwede, W.; Skuballa, W. The use of epothilones in the treatment of brain diseases associated with proliferative process. *WO 03/074053 A1.* 2003.
86. Andrieux A, Salin P, Schweitzer A, Begou M, Pachoud B, Brun P, Gory-Faure S, Kujala P, Suaud-Chagny MF, Hofle G, Job D. Microtubule Stabilizer Ameliorates Synaptic Function and Behavior in a Mouse Model for Schizophrenia. *Biol Psychiatry.* 2006; 60:1224–1230. [PubMed: 16806091]
87. Lee CB, Wu Z, Zhang F, Chappell MD, Stachel SJ, Chou TC, Guan Y, Danishefsky SJ. Insights into long-range structural effects on the stereochemistry of aldol condensations: a practical total synthesis of desoxyepothilone F. *J Am Chem Soc.* 2001; 123:5249–5259. [PubMed: 11457387]
88. Rivkin A, Yoshimura F, Gabarda AE, Cho YS, Chou TC, Dong H, Danishefsky SJ. Discovery of (E)-9,10-dehydroepothilones through chemical synthesis: on the emergence of 26-trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a promising anticancer drug candidate. *J Am Chem Soc.* 2004; 126:10913–10922. [PubMed: 15339176]
89. Laferriere N, MacRae T, Brown D. Tubulin synthesis and assembly in differentiating neurons. *Biochem Cell Biol.* 1997; 75:103–117. [PubMed: 9250358]
90. Black M, Baas P, Humphries S. Dynamics of alpha-tubulin deacetylation in intact neurons. *J Neurosci.* 1989; 9:358–368. [PubMed: 2563279]
91. Balog A, Meng D, Kamenecka T, Bertinato P, Su DS, Sorensen EJ, Danishefsky SJ. Total Synthesis of (–)-Epothilone A. *Angew Chem Int Ed Engl.* 1996; 35:2801–2803.

92. Yang Z, He Y, Vourloumis D, Vallberg H, Nicolaou KC. Total Synthesis of Epothilone A: The Olefin Metathesis Approach. *Angew Chem Int Ed Engl.* 1997; 36:166–168.
93. Schinzer D, Limberg A, Bauer A, Bohm OM, Cordes M. Total Synthesis of (–)-Epothilone A. *Angew Chem Int Ed Engl.* 1997; 36:523–524.
94. Altmann, K-H.; Hofle, G.; Muller, R.; Mulzer, JKP. *Epothilones: An Outstanding Family of Anti-Tumor Agents.* Springer; Wien New York: 2009.
95. Conlin A, Fornier M, Hudis C, Kar S, Kirkpatrick P. Ixabepilone. *Nat Rev Drug Discov.* 2007; 6:953–954.
96. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. *Angew Chem Int Ed Engl.* 2006; 45:7942–7948. [PubMed: 17006870]
97. Klar U, Hoffmann J, Giurescu M. Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate. *Expert Opin Investig Drugs.* 2008; 17:1735–1748.
98. Gunasekera SP, Gunasekera M, Longley RE, Schulte GK. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge *Discodermia dissoluta*. *J Org Chem.* 1990; 55:4912–4915.
99. Longley RE, Caddigan D, Harmody D, Gunasekera M, Gunasekera SP. Discodermolide--a new, marine-derived immunosuppressive compound. I. In vitro studies. *Transplantation.* 1991; 52:650–656. [PubMed: 1833864]
100. Longley RE, Caddigan D, Harmody D, Gunasekera M, Gunasekera SP. Discodermolide--a new, marine-derived immunosuppressive compound. II. In vivo studies. *Transplantation.* 1991; 52:656–661. [PubMed: 1926345]
101. ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, Rosenkranz HS, Day BW. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. *Biochemistry.* 1996; 35:243–250. [PubMed: 8555181]
102. Hung DT, Chen J, Schreiber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. *Chem Biol.* 1996; 3:287–293. [PubMed: 8807856]
103. Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. *Mol Pharmacol.* 1997; 52:613–622. [PubMed: 9380024]
104. Xia S, Kenesky CS, Rucker PV, Smith AB, Orr GA, Horwitz SB. A photoaffinity analogue of discodermolide specifically labels a peptide in beta-tubulin. *Biochemistry.* 2006; 45:11762–11775. [PubMed: 17002277]
105. Martello LA, LaMarche MJ, He L, Beauchamp TJ, Smith AB 3rd, Horwitz SB. The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies. *Chem Biol.* 2001; 8:843–855. [PubMed: 11564553]
106. Khrapunovich-Baine M, Menon V, Verdier-Pinard P, Smith AB, Angeletti RH, Fiser A, Horwitz SB, Xiao H. Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization. *Biochemistry.* 2009; 48:11664–11677. [PubMed: 19863156]
107. Honore S, Kamath K, Braguer D, Horwitz SB, Wilson L, Briand C, Jordan MA. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. *Cancer Res.* 2004; 64:4957–4964. [PubMed: 15256469]
108. Martello LA, McDaid HM, Regl DL, Yang CP, Meng D, Pettus TR, Kaufman MD, Arimoto H, Danishefsky SJ, Smith AB 3rd, Horwitz SB. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. *Clin Cancer Res.* 2000; 6:1978–1987. [PubMed: 10815923]
109. Huang GS, Lopez-Barcons L, Freeze BS, Smith AB III, Goldberg GL, Horwitz SB, McDaid HM. Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. *Clin Cancer Res.* 2006; 12:298–304. [PubMed: 16397055]
110. Hung DT, Nerenberg JB, Schreiber SL. Syntheses of Discodermolides Useful for Investigating Microtubule Binding and Stabilization. *J Am Chem Soc.* 1996; 118:11054–11080.

111. Nerenberg JB, Hung DT, Somers PK, Schreiber SL. Total synthesis of the immunosuppressive agent (-)-discodermolide. *J Am Chem Soc.* 1993; 115:12621–12622.
112. Smith AB III, Freeze BS. (+)-Discodermolide: total synthesis construction of novel analogues and biological evaluation. *Tetrahedron.* 2008; 64:261–298. [PubMed: 21113402]
113. Smith AB 3rd, Kaufman MD, Beauchamp TJ, LaMarche MJ, Arimoto H. Gram-scale synthesis of (+)-discodermolide. *Org Lett.* 1999; 1:1823–1826. [PubMed: 10836041]
114. Smith AB 3rd, Beauchamp TJ, LaMarche MJ, Kaufman MD, Qiu Y, Arimoto H, Jones DR, Kobayashi K. Evolution of a Gram-Scale Synthesis of (+)-Discodermolide. *J Am Chem Soc.* 2000; 122:8654–8664.
115. Paterson I, Florence GJ, Gerlach K, Scott JP. Total Synthesis of the Antimicrotubule Agent (+)-Discodermolide Using Boron-Mediated Aldol Reactions of Chiral Ketones. *Angew Chem Int Ed Engl.* 2000; 39:377–380. [PubMed: 10649416]
116. Mita A, Lockhart AC, Chen TL, Bochinski K, Curtright J, Cooper W, Hammond L, Rothenberg M, Rowinsky E, Sharma S. A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. *J Clin Oncol ASCO Annu Meet Proc.* 2004; 14S:2025.
117. Paterson I, Gardner NM. Design, synthesis and biological evaluation of a macrocyclic discodermolide/dictyostatin hybrid. *Chem Commun (Camb).* 2007:49–51. [PubMed: 17279257]
118. Smith AB, Sugasawa K, Atasoylu O, Yang CPH, Horwitz SB. Design and Synthesis of (+)-Discodermolide–Paclitaxel Hybrids Leading to Enhanced Biological Activity. *J Med Chem.* 2011; 54:6319–6327. [PubMed: 21870795]
119. Burlingame MA, Shaw SJ, Sundermann KF, Zhang D, Petryka J, Mendoza E, Liu F, Myles DC, LaMarche MJ, Hirose T, Freeze SB, Smith AB 3rd. Design, synthesis and cytotoxicity of 7-deoxy aryl discodermolide analogues. *Bioorg Med Chem Lett.* 2004; 14:2335–2338. [PubMed: 15081036]
120. Shaw SJ, Sundermann KF, Burlingame MA, Myles DC, Freeze BS, Xian M, Brouard I, Smith AB 3rd. Toward understanding how the lactone moiety of discodermolide affects activity. *J Am Chem Soc.* 2005; 127:6532–6533. [PubMed: 15869264]
121. Pettit GR, Cichacz ZA, Gao F, Boyd MR, Schmidt JM. Isolation and structure of the cancer cell growth inhibitor dictyostatin 1. *J Chem Soc, Chem Commun.* 1994:1111–1112.
122. Isbrucker RA, Cummins J, Pomponi SA, Longley RE, Wright AE. Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. *Biochem Pharmacol.* 2003; 66:75–82. [PubMed: 12818367]
123. Madiraju C, Edler MC, Hamel E, Raccor BS, Balachandran R, Zhu G, Giuliano KA, Vogt A, Shin Y, Fournier JH, Fukui Y, Bruckner AM, Curran DP, Day BW. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. *Biochemistry.* 2005; 44:15053–15063. [PubMed: 16274252]
124. Smith AB, LaMarche MJ, Falcone-Hindley M. Solution Structure of (+)-Discodermolide. *Org Lett.* 2001; 3:695–698. [PubMed: 11259039]
125. Canales A, Matesanz R, Gardner NM, Andreu JM, Paterson I, Diaz JF, Jimenez-Barbero J. The Bound Conformation of Microtubule-Stabilizing Agents: NMR Insights into the Bioactive 3D Structure of Discodermolide and Dictyostatin. *Chemistry – A European Journal.* 2008; 14:7557–7569.
126. Sanchez-Pedregal VM, Kubicek K, Meiler J, Lyothier I, Paterson I, Carlomagno T. The Tubulin-Bound Conformation of Discodermolide Derived by NMR Studies in Solution Supports a Common Pharmacophore Model for Epothilone and Discodermolide. *Angew Chem Int Ed.* 2006; 45:7388–7394.
127. Paterson I, Britton R, Delgado O, Meyer A, Poullennec KG. Total Synthesis and Configurational Assignment of (-)-Dictyostatin, a Microtubule-Stabilizing Macrolide of Marine Sponge Origin. *Angew Chem Int Ed.* 2004; 43:4629–4633.
128. Shin Y, Fournier JH, Fukui Y, Bruckner AM, Curran DP. Total Synthesis of (-)-Dictyostatin: Confirmation of Relative and Absolute Configurations. *Angew Chem Int Ed.* 2004; 43:4634–4637.

129. Ramachandran PV, Srivastava A, Hazra D. Total Synthesis of Potential Antitumor Agent, (–)-Dictyostatin. *Org Lett.* 2006; 9:157–160. [PubMed: 17192109]
130. O’Nei GW, Phillips AJ. Total Synthesis of (–)-Dictyostatin. *J Am Chem Soc.* 2006; 128:5340–5341. [PubMed: 16620095]
131. Paterson I, Britton R, Delgado O, Gardner NM, Meyer A, Naylor GJ, Poullennec KG. Total synthesis of (–)-dictyostatin, a microtubule-stabilising anticancer macrolide of marine sponge origin. *Tetrahedron.* 2010; 66:6534–6545.
132. Lindel T, Jensen PR, Fenical W, Long BH, Casazza AM, Carboni J, Fairchild CR. Eleutherobin, a New Cytotoxin that Mimics Paclitaxel (Taxol) by Stabilizing Microtubules. *J Am Chem Soc.* 1997; 119:8744–8745.
133. Long BH, Carboni JM, Wasserman AJ, Cornell LA, Casazza AM, Jensen PR, Lindel T, Fenical W, Fairchild CR. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol (R)). *Cancer Res.* 1998; 58:1111–1115. [PubMed: 9515790]
134. D’Ambrosio M, Guerriero A, Pietra F. Sarcodictyin A and Sarcodictyin B, Novel Diterpenoidic Alcohols Esterified by (E)-N(1)-Methylurocanic Acid. Isolation from the Mediterranean *Stolonifer Sarcodictyon roseum*. *Helv Chim Acta.* 1987; 70:2019–2027.
135. D’Ambrosio M, Guerriero A, Pietra F. Isolation from the Mediterranean *Stolonifer* Coral *Sarcodictyon roseum* of Sarcodictyin C, D, E, and F, novel diterpenoidic alcohols esterified by (E)- or (Z)-N(1)-methylurocanic acid. Failure of the carbon-skeleton type as a classification criterion. *Helv Chim Acta.* 1988; 71:964–976.
136. Ciomei M, Albanese C, Pastori W, Grandi M, Pietra F, D’Ambrosio M, Guerriero A, Battistini C. Sarcodictyins: a new class of marine derivatives with mode of action similar to Taxol. Abstract 30, *Proc Am Ass Canc Res.* 1997; 38:5.
137. Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. *Biochemistry.* 1999; 38:5490–5498. [PubMed: 10220336]
138. McDaid HM, Bhattacharya SK, Chen XT, He L, Shen HJ, Gutteridge CE, Horwitz SB, Danishefsky SJ. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines. *Cancer Chemother Pharmacol.* 1999; 44:131–137. [PubMed: 10412947]
139. Nicolaou KC, Xu JY, Kim S, Ohshima T, Hosokawa S, Pfefferkorn J. Synthesis of the Tricyclic Core of Eleutherobin and Sarcodictyins and Total Synthesis of Sarcodictyin A. *J Am Chem Society.* 1997; 119:11353–11354.
140. Nicolaou KC, van Delft F, Ohshima T, Vourloumis D, Xu J, Hosokawa S, Pfefferkorn J, Kim S, Li T. Total Synthesis of Eleutherobin. *Angew Chem Int Ed Engl.* 1997; 36:2520–2524.
141. Nicolaou KC, Ohshima T, Hosokawa S, van Delft FL, Vourloumis D, Xu JY, Pfefferkorn J, Kim S. Total Synthesis of Eleutherobin and Eleuthosides A and B. *J Am Chem Soc.* 1998; 120:8674–8680.
142. Nicolaou KC, Xu JY, Kim S, Pfefferkorn J, Ohshima T, Vourloumis D, Hosokawa S. Total Synthesis of Sarcodictyins A and B. *J Am Chem Society.* 1998; 120:8661–8673.
143. Chen XT, Bhattacharya SK, Zhou B, Gutteridge CE, Pettus TRR, Danishefsky SJ. The Total Synthesis of Eleutherobin. *J Am Chem Soc.* 1999; 121:6563–6579.
144. Chen XT, Gutteridge CE, Bhattacharya SK, Zhou B, Pettus TRR, Hascall T, Danishefsky SJ. A Convergent Route for the Total Synthesis of the Eleuthesides. *Angew Chem Int Ed.* 1998; 37:185–186.
145. Chen XT, Zhou B, Bhattacharya SK, Gutteridge CE, Pettus TRR, Danishefsky SJ. The Total Synthesis of Eleutherobin: A Surprise Ending. *Angew Chem Int Ed.* 1998; 37:789–792.
146. Corley DG, Herb R, Moore RE, Scheuer PJ, Paul VJ. Laulimalide. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator. *J Org Chem.* 1988; 53:3644–3646.
147. Quinoa E, Kakou Y, Crews P. Fijianolides, polyketide heterocyclics from amarine sponge. *J Org Chem.* 1988; 53:3642–3644.
148. Jefford CW, Bernardinelli G, Tanaka J-i, Higa T. Structures and absolute configurations of the marine toxins, latrunculin A and laulimalide. *Tet Lett.* 1996; 37:159–162.

149. Mooberry SL, Tien G, Hernandez AH, Plubrukarn A, Davidson BS. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. *Cancer Res.* 1999; 59:653–660. [PubMed: 9973214]
150. Pryor DE, O'Brate A, Bilcer G, Diaz JF, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK. The Microtubule Stabilizing Agent Laulimalide Does Not Bind in the Taxoid Site, Kills Cells Resistant to Paclitaxel and Epothilones, and May Not Require Its Epoxide Moiety for Activity. *Biochemistry.* 2002; 41:9109–9115. [PubMed: 12119025]
151. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. *Proc Natl Acad Sci U S A.* 2000; 97:2904–2909. [PubMed: 10688884]
152. Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK, Curran DP, Cushman M, Nicolaou KC, Paterson I. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. *Mol Pharmacol.* 2006; 70:1555–1564. [PubMed: 16887932]
153. Bennett MJ, Barakat K, Huzil JT, Tuszynski J, Schriemer DC. Discovery and Characterization of the Laulimalide-Microtubule Binding Mode by Mass Shift Perturbation Mapping. *Chem Biol.* 2010; 17:725–734. [PubMed: 20659685]
154. Ghosh AK, Wang Y. Total Synthesis of (–)-Laulimalide. *J Am Chem Soc.* 2000; 122:11027–11028.
155. Mulzer J, Ohler E. Microtubule-stabilizing marine metabolite laulimalide and its derivatives: Synthetic approaches and antitumor activity. *Chem Rev.* 2003; 103:3753–3786. [PubMed: 12964883]
156. Gallagher BM, Fang FG, Johannes CW, Pesant M, Tremblay MR, Zhao H, Akasaka K, Li XY, Liu J, Littlefield BA. Synthesis and biological evaluation of (–)-laulimalide analogues. *Bioorg Med Chem Lett.* 2004; 14:575–579. [PubMed: 14741246]
157. Liu J, Towle MJ, Cheng H, Saxton P, Reardon C, Wu J, Murphy EA, Kuznetsov G, Johannes CW, Tremblay MR, Zhao H, Pesant M, Fang FG, Vermeulen MW, Gallagher BM, Littlefield BA. In vitro and in vivo anticancer activities of synthetic (–)-laulimalide, a marine natural product microtubule stabilizing agent. *Anticancer Res.* 2007; 27:1509–1518. [PubMed: 17595769]
158. Johnson TA, Tenney K, Cichewicz RH, Morinaka BI, White KN, Amagata T, Subramanian B, Media J, Mooberry SL, Valeriote FA, Crews P. Sponge-derived fijianolide polyketide class: further evaluation of their structural and cytotoxicity properties. *J Med Chem.* 2007; 50:3795–3803. [PubMed: 17622130]
159. West LM, Northcote PT, Battershill CN. Peloruside A: a potent cytotoxic macrolide isolated from the new zealand marine sponge *Mycale* sp. *J Org Chem.* 2000; 65:445–449. [PubMed: 10813954]
160. Hood KA, Backstrom BT, West LM, Northcote PT, Berridge MV, Miller JH. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C. *Anticancer Drug Des.* 2001; 16:155–166. [PubMed: 11962513]
161. Gaitanos TN, Buey RM, Diaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. *Cancer Res.* 2004; 64:5063–5067. [PubMed: 15289305]
162. Huzil JT, Chik JK, Slys GW, Freedman H, Tuszynski J, Taylor RE, Sackett DL, Schriemer DC. A Unique Mode of Microtubule Stabilization Induced by Peloruside A. *J Mol Biol.* 2008; 378:1016–1030. [PubMed: 18405918]
163. Wilmes A, O'Sullivan D, Chan A, Chandrasen C, Paterson I, Northcote PT, La Flamme AC, Miller JH. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells. *Cancer Chemother Pharmacol.* 2011; 68:117–126. [PubMed: 20848285]
164. Liao X, Wu Y, De Brabander JK. Total synthesis and absolute configuration of the novel microtubule-stabilizing agent peloruside A. *Angew Chem Int Ed Engl.* 2003; 42:1648–1652. [PubMed: 12698467]

165. Jin M, Taylor RE. Total synthesis of (+)-peloruside A. *Org Lett.* 2005; 7:1303–1305. [PubMed: 15787492]
166. Ghosh AK, Xu X, Kim JH, Xu CX. Enantioselective Total Synthesis of Peloruside A: A Potent Microtubule Stabilizer. *Org Lett.* 2008; 10:1001–1004. [PubMed: 18247632]
167. Evans DA, Welch DS, Speed AW, Moniz GA, Reichelt A, Ho S. An aldol-based synthesis of (+)-peloruside a, a potent microtubule stabilizing agent. *J Am Chem Soc.* 2009; 131:3840–3841. [PubMed: 19249829]
168. Smith AB, Cox JM, Furuichi N, Kenesky CS, Zheng J, Atasoylu O, Wuest WM. Total Synthesis of (–)-2-epi-Peloruside A. *Org Lett.* 2008; 10:5501–5504. [PubMed: 19007239]
169. McGowan MA, Stevenson CP, Schiffler MA, Jacobsen EN. An Enantioselective Total Synthesis of (+)-Peloruside A. *Angew Chem.* 2010; 122:6283–6286.
170. Hoye TR, Jeon J, Kopel LC, Ryba TD, Tennakoon MA, Wang Y. Total Synthesis of Peloruside A through Kinetic Lactonization and Relay Ring-Closing Metathesis Cyclization Reactions. *Angew Chem Int Ed.* 2010; 49:6151–6155.
171. Dalby SM, Paterson I. Synthesis of polyketide natural products and analogs as promising anticancer agents. *Curr Opin Drug Discov Devel.* 2010; 13:777–794.
172. Singh AJ, Xu CX, Xu X, West LM, Wilmes A, Chan A, Hamel E, Miller JH, Northcote PT, Ghosh AK. Peloruside B, A Potent Antitumor Macrolide from the New Zealand Marine Sponge *Mycale hentscheli*: Isolation, Structure, Total Synthesis, and Bioactivity. *J Org Chem.* 2009; 75:2–10. [PubMed: 19957922]
173. Singh AJ, Razzak M, Teesdale-Spittle P, Gaitanos TN, Wilmes A, Paterson I, Goodman JM, Miller JH, Northcote PT. Structure-activity studies of the pelorusides: new congeners and semi-synthetic analogues. *Org Biomol Chem.* 2011; 9:4456–4466. [PubMed: 21512693]
174. Sato B, Muramatsu H, Miyauchi M, Hori Y, Takase S, Hino M, Hashimoto S, Terano H. A new antimitotic substance, FR182877. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. *J Antibiot (Tokyo).* 2000; 53:123–130. [PubMed: 10805571]
175. Sato B, Nakajima H, Hori Y, Hino M, Hashimoto S, Terano H. A new antimitotic substance, FR182877. II. The mechanism of action. *J Antibiot (Tokyo).* 2000; 53:204–206. [PubMed: 10805584]
176. Yoshimura S, Sato B, Kinoshita T, Takase S, Terano H. A new antimitotic substance, FR182877. III. Structure determination. *J Antibiot (Tokyo).* 2000; 53:615–22. [(2002) *J. Antibiot.* 55, p C-1 (errata)]. [PubMed: 10966078]
177. Vanderwal CD, Vosburg DA, Weiler S, Sorensen EJ. An Enantioselective Synthesis of FR182877 Provides a Chemical Rationalization of Its Structure and Affords Multigram Quantities of Its Direct Precursor. *J Am Chem Soc.* 2003; 125:5393–5407. [PubMed: 12720453]
178. Vosburg DA, Vanderwal CD, Sorensen EJ. A Synthesis of (+)-FR182877, Featuring Tandem Transannular Diels–Alder Reactions Inspired by a Postulated Biogenesis. *J Am Chem Soc.* 2002; 124:4552–4553. [PubMed: 11971689]
179. Evans DA, Starr JT. A Cascade Cycloaddition Strategy Leading to the Total Synthesis of (–)-FR182877. *Angew Chem Int Ed.* 2002; 41:1787–1790.
180. Edler MC, Buey RM, Gussio R, Marcus AI, Vanderwal CD, Sorensen EJ, Diaz JF, Giannakakou P, Hamel E. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site. *Biochemistry.* 2005; 44:11525–11538. [PubMed: 16114889]
181. Buey RM, Calvo E, Barasoain I, Pineda O, Edler MC, Matesanz R, Cerezo G, Vanderwal CD, Day BW, Sorensen EJ, Lopez JA, Andreu JM, Hamel E, Diaz JF. Cyclostreptin binds covalently to microtubule pores and luminal taxoid binding sites. *Nat Chem Biol.* 2007; 3:117–125. [PubMed: 17206139]
182. Prussia AJ, Yang Y, Geballe MT, Snyder JP. Cyclostreptin and microtubules: is a low-affinity binding site required? *Chembiochem.* 2010; 11:101–109. [PubMed: 19946930]
183. Field, Jessica J.; Pera, B.; Calvo, E.; Canales, A.; Zurwerra, D.; Trigili, C.; Rodriguez-Salarichs, J.; Matesanz, R.; Kanakkanthara, A.; Wakefield, S.J.; Singh, A.J.; Jimenez-Barbero, J.; Northcote, P.; Miller, John H.; Lopez, Juan A.; Hamel, E.; Barasoain, I.; Altmann, K.H.; Diaz, Jose F. Zampanolide, a Potent New Microtubule-Stabilizing Agent, Covalently Reacts with the Taxane

- Luminal Site in Tubulin α , β -Heterodimers and Microtubules. *Chem Biol.* 2012; 19:686–698. [PubMed: 22726683]
184. Scheuer P, Swanholm C, Madamba L, Hudgins W. The constituents of *Tacca leontopetaloides*. *Lloydia.* 1963; 26:133–140.
185. Chen Z, Wang B, Chen M. Steroidal bitter principles from *Tacca plantaginea* structures of taccalonolide A and B. *Tet Lett.* 1987; 28:1673–1675.
186. Chen ZL, Wang B-d, Shen JH. Taccalonolide C and D, two pentacyclic steroids of *Tacca plantaginea*. *Phytochemistry.* 1988; 27:2999–3001.
187. Yang JY, Zhao RH, Chen CX, Ni W, Teng F, Hao XJ, Liu HY. Taccalonolides W–Y, Three New Pentacyclic Steroids from *Tacca plantaginea*. *Helv Chim Acta.* 2008; 91:1077–1082.
188. Peng J, Risinger AL, Fest GA, Jackson EM, Helms G, Polin LA, Mooberry SL. Identification and Biological Activities of New Taccalonolide Microtubule Stabilizers. *J Med Chem.* 2011; 54:6117–6124. [PubMed: 21800839]
189. Li J, Risinger AL, Peng J, Chen Z, Hu L, Mooberry SL. Potent Taccalonolides, AF and AJ, Inform Significant Structure–Activity Relationships and Tubulin as the Binding Site of These Microtubule Stabilizers. *J Am Chem Soc.* 2011; 133:19064–19067. [PubMed: 22040100]
190. Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, Quada JC Jr, Hemscheidt TK, Mooberry SL. Taccalonolides E and A: Plant-derived Steroids with Microtubule-stabilizing Activity. *Cancer Res.* 2003; 63:3211–3220. [PubMed: 12810650]
191. Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Luduena RF, Kruh GD, Mooberry SL. The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms. *Cancer Res.* 2008; 68:8881–8888. [PubMed: 18974132]
192. Buey RM, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, Mooberry S, Andreu JM, Diaz JF. Microtubule Interactions with Chemically Diverse Stabilizing Agents: Thermodynamics of Binding to the Paclitaxel Site Predicts Cytotoxicity. *Chem Biol.* 2005; 12:1269–1279. [PubMed: 16356844]
193. Risinger AL, Mooberry SL. Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel. *Cell Cycle.* 2011; 10:2162–2171. [PubMed: 21597323]
194. Tanaka, J-i; Higa, T. Zampanolide, a new cytotoxic macrolide from a marine sponge. *Tet Lett.* 1996; 37:5535–5538.
195. Cutignano A, Bruno I, Bifulco G, Casapullo A, Debitus C, Gomez-Paloma L, Riccio R. Dactylolide, a New Cytotoxic Macrolide from the Vanuatu Sponge *Dactylospongia* sp. *Eur J Org Chem.* 2001; 2001:775–778.
196. Smith AB, Safonov IG, Corbett RM. Total Synthesis of (+)-Zampanolide. *J Am Chem Soc.* 2001; 123:12426–12427. [PubMed: 11734051]
197. Smith AB, Safonov IG, Corbett RM. Total Syntheses of (+)-Zampanolide and (+)-Dactylolide Exploiting a Unified Strategy. *J Am Chem Soc.* 2002; 124:11102–11113. [PubMed: 12224958]
198. Hoye TR, Hu M. Macrolactonization via Ti(IV)-Mediated Epoxy-Acid Coupling: A Total Synthesis of (–)-Dactylolide [and Zampanolide]. *J Am Chem Soc.* 2003; 125:9576–9577. [PubMed: 12904009]
199. Uenishi, Ji; Iwamoto, T.; Tanaka, J. Total Synthesis of (–)-Zampanolide and Questionable Existence of (–)-Dactylolide as the Elusive Biosynthetic Precursor of (–)-Zampanolide in an Okinawan Sponge. *Org Lett.* 2009; 11:3262–3265. [PubMed: 19586001]
200. Ghosh AK, Cheng X, Bai R, Hamel E. Total Synthesis of Potent Antitumor Macrolide (–)-Zampanolide: An Oxidative Intramolecular Cyclization-Based Strategy. *Eur J Org Chem.* 2012:4130–4139.
201. Smith AB, Safonov IG. Total Synthesis of (+)-Dactylolide. *Org Lett.* 2002; 4:635–637. [PubMed: 11843610]
202. Aubele DL, Wan S, Floreancig PE. Total Synthesis of (+)-Dactylolide through an Efficient Sequential Peterson Olefination and Prins Cyclization Reaction. *Angew Chem Int Ed.* 2005; 44:3485–3488.
203. Sanchez CC, Keck GE. Total Synthesis of (+)-Dactylolide. *Org Lett.* 2005; 7:3053–3056. [PubMed: 15987203]

204. Ding F, Jennings MP. Total Synthesis of (–)-Dactyloide and Formal Synthesis of (–)-Zampanolide via Target Oriented β -C-Glycoside Formation. *J Org Chem.* 2008; 73:5965–5976. [PubMed: 18588348]
205. Louis I, Hungerford NL, Humphries EJ, McLeod MD. Enantioselective Total Synthesis of (–)-Dactyloide. *Org Lett.* 2006; 8:1117–1120. [PubMed: 16524282]
206. Field JJ, Singh AJ, Kanakkanthara A, Halafihi Ti, Northcote PT, Miller JH. Microtubule-Stabilizing Activity of Zampanolide, a Potent Macrolide Isolated from the Tongan Marine Sponge *Cacospongia mycofijiensis*. *J Med Chem.* 2009; 52:7328–7332. [PubMed: 19877653]
207. Zurwerra D, Gertsch, Altmann KH. Synthesis of (–)-Dactyloide and 13-Desmethylene(–)-dactyloide and Their Effects on Tubulin. *Org Lett.* 2010; 12:2302–2305. [PubMed: 20415434]
208. Manzo E, van Soest R, Matainaho L, Roberge M, Andersen RJ. Ceratamines A and B, antimitotic heterocyclic alkaloids isolated from the marine sponge *Pseudoceratina* sp. collected in Papua New Guinea. *Org Lett.* 2003; 5:4591–4594. [PubMed: 14627391]
209. Karjala G, Chan Q, Manzo E, Andersen RJ, Roberge M. Ceratamines, structurally simple microtubule-stabilizing antimitotic agents with unusual cellular effects. *Cancer Res.* 2005; 65:3040–3043. [PubMed: 15833830]
210. Coleman RS, Campbell EL, Carper DJ. A Direct and Efficient Total Synthesis of the Tubulin-Binding Agents Ceratamine A and B; Use of IBX for a Remarkable Heterocycle Dehydrogenation. *Org Lett.* 2009; 11:2133–2136. [PubMed: 19385610]
211. Nodwell M, Zimmerman C, Roberge M, Andersen RJ. Synthetic Analogues of the Microtubule-Stabilizing Sponge Alkaloid Ceratamine A Are More Active than the Natural Product. *J Med Chem.* 2010; 53:7843–7851. [PubMed: 20945907]
212. Nodwell M, Riffell JL, Roberge M, Andersen RJ. Synthesis of antimitotic analogs of the microtubule stabilizing sponge alkaloid ceratamine A. *Org Lett.* 2008; 10:1051–1054. [PubMed: 18278926]
213. Madari H, Panda D, Wilson L, Jacobs RS. Dicummarol: a unique microtubule stabilizing natural product that is synergistic with Taxol. *Cancer Res.* 2003; 63:1214–1220. [PubMed: 12649179]
214. Miglietta A, Gabriel L, Appendino G, Bocca C. Biological properties of jatrophane polyesters, new microtubule-interacting agents. *Cancer Chemother Pharmacol.* 2003; 51:67–74. [PubMed: 12497208]
215. Mooberry SL, Stratman K, Moore RE. Tubercidin stabilizes microtubules against vinblastine-induced depolymerization, a taxol-like effect. *Cancer Lett.* 1995; 96:261–266. [PubMed: 7585466]
216. Crabtree DV, Ojima I, Geng X, Adler AJ. Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site. *Bioorg Med Chem.* 2001; 9:1967–1976. [PubMed: 11504633]
217. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Breneman DE, Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. *J Neurochem.* 1999; 72:1283–1293. [PubMed: 10037502]
218. Gozes I. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). *Curr Pharm Des.* 2011; 17:3413–3417. [PubMed: 21902667]
219. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). *CNS Drug Rev.* 2005; 11:353–368. [PubMed: 16614735]
220. Gozes I. Davunetide (AL-108): Targeting tangles. *Alzheimers Dement.* 2009; 5:74–74.
221. Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. *J Biol Chem.* 2004; 279:28531–28538. [PubMed: 15123709]
222. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. *J Neurochem.* 2006; 98:973–984. [PubMed: 16893427]

223. Yenjerla M, LaPointe NE, Lopus M, Cox C, Jordan MA, Feinstein SC, Wilson L. The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. *J Alzheimers Dis.* 2010; 19:1377–1386. [PubMed: 20061604]
224. Shintani Y, Tanaka T, Nozaki Y. GS-164, a small synthetic compound, stimulates tubulin polymerization by a similar mechanism to that of Taxol. *Cancer Chemother Pharmacol.* 1997; 40:513–520. [PubMed: 9332466]
225. Wang Z, Yang D, Mohanakrishnan AK, Fanwick PE, Nampoothiri P, Hamel E, Cushman M. Synthesis of B-Ring Homologated Estradiol Analogues that Modulate Tubulin Polymerization and Microtubule Stability. *J Med Chem.* 2000; 43:2419–2429. [PubMed: 10882369]
226. Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J, Freeman D, Robey RW, Werbovetz K, Lewis A, Li C. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. *Mol Cancer Ther.* 2006; 5:450–456. [PubMed: 16505120]
227. Zhang N, Ayril-Kaloustian S, Nguyen T, Afragola J, Hernandez R, Lucas J, Gibbons J, Beyer C. Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition. *J Med Chem.* 2007; 50:319–327. [PubMed: 17228873]
228. Zhang N, Ayril-Kaloustian S, Nguyen T, Hernandez R, Lucas J, Discafani C, Beyer C. Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anticancer agents. *Bioorg Med Chem.* 2009; 17:111–118. [PubMed: 19041247]
229. Crowley PJ, Lamberth C, Muller U, Wendeborn S, Nebel K, Williams J, Sageot OA, Carter N, Mathie T, Kempf HJ, Godwin J, Schneiter P, Dobler MR. Synthesis and fungicidal activity of tubulin polymerisation promoters. Part 1: pyrido[2,3-b]pyrazines. *Pest Manag Sci.* 2010; 66:178–185. [PubMed: 19795441]
230. Crowley PJ, Lamberth C, Muller U, Wendeborn S, Sageot OA, Williams J, Bartovič A. Niementowski-type synthesis of pyrido[3,2-e][1,2,4]triazines: potent *aza*-analogs of pyrido[2,3-b]pyrazine fungicides. *Tet Lett.* 2010; 51:2652–2654.
231. Lamberth C, Trah S, Wendeborn S, Dumeunier R, Courbot M, Godwin J, Schneiter P. Synthesis and fungicidal activity of tubulin polymerisation promoters. Part 2: Pyridazines. *Bioorg Med Chem.* 2012; 20:2803–2810. [PubMed: 22494843]
232. Beyer CF, Zhang N, Hernandez R, Vitale D, Lucas J, Nguyen T, Discafani C, Ayril-Kaloustian S, Gibbons JJ. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. *Cancer Res.* 2008; 68:2292–300. [PubMed: 18381436]
233. Beyer CF, Zhang N, Hernandez R, Vitale D, Nguyen T, Ayril-Kaloustian S, Gibbons JJ. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties. *Cancer Chemother Pharmacol.* 2009; 64:681–689. [PubMed: 19132373]
234. Ayril-Kaloustian S, Zhang N, Beyer C. Cevipabulin (TTI-237): preclinical and clinical results for a novel antimicrotubule agent. *Methods Find Exp Clin Pharmacol.* 2009; 31:443–447. [PubMed: 19907719]
235. Lee VMY, Brunden KR, Hutton M, Trojanowski JQ. Developing Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal Protein Targets. *Cold Spring Harbor Perspectives in Medicine.* 2011; 1:a006437. [PubMed: 22229117]
236. Brunden KR, Trojanowski JQ, Lee VMY. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. *Nat Rev Drug Discov.* 2009; 8:783–793. [PubMed: 19794442]

Biographies

Carlo Ballatore is a Research Assistant Professor at the University of Pennsylvania Perelman School of Medicine, Center for Neurodegenerative Disease Research. His research focuses on medicinal chemistry and drug discovery particularly in the area of Alzheimer's disease and related tauopathies. He graduated in Chemistry and Pharmaceutical Technologies at University of Rome "La Sapienza", Italy. He obtained a Ph.D. in Medicinal Chemistry at the University of Wales, Cardiff, U.K., and then did a post-doctoral fellowship at the M.D. Anderson Cancer Center, University of Texas, Houston.

Kurt R. Brunden is Director of Drug Discovery and Research Professor in the Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania, where he oversees programs in the areas of Alzheimer's disease, frontotemporal lobar degeneration and Parkinson's disease. Prior to joining CNDR in 2007, Dr. Brunden served as Vice President in two public biotechnology companies, leading drug discovery programs in a number of therapeutic areas. Earlier in his career, Dr. Brunden was an NIH-funded faculty member within the Biochemistry Department at the University of Mississippi Medical Center. He obtained his B.S. degree from Western Michigan University, with dual majors of Biology and Health Chemistry, and his Ph.D. in Biochemistry from Purdue University, with a post-doctoral fellowship at the Mayo Clinic.

Dr. Donna M. Huryn is an Adjunct Professor in the Department of Chemistry at the University of Pennsylvania, and Research Professor at the School of Pharmacy, University of Pittsburgh. She received a Ph.D. in Organic Chemistry from the University of Pennsylvania, then spend 18 years in the pharmaceutical industry at Hoffmann-LaRoche, Inc and Wyeth Research. At Wyeth, she led the CNS Medicinal Chemistry and Chemical Sciences Interface Departments, and oversaw programs in Alzheimer's Disease, schizophrenia, depression, multiple sclerosis and asthma. She joined academia in 2004, where her research interests lie in the identification of small molecule probes to interrogate biological pathways in the area of neurodegeneration, cancer and infectious diseases. Professor Huryn is a Fellow of the American Chemical Society.

John Q. Trojanowski obtained his MD/PhD in 1976 from Tufts University, and after training at Harvard and Penn, became Penn faculty in 1981 where he is Professor, and directs the NIA Alzheimer's Center, the NINDS Udall Parkinson's Center and Institute on Aging at Penn. His research focuses on neurodegenerative diseases, and he is an ISI Highly Cited Researcher (among the top 5 most highly cited neuroscientists from 1997–2007). He was elected to the Institute of Medicine in 2002 and led an effort to make a PBS film ("Alzheimer's Disease-Facing the Facts") that won a 2009 Emmy Award for best documentary.

Virginia M.-Y. Lee obtained her Ph.D. in Biochemistry, University of California San Francisco (1973) and an MBA at the Wharton School (1984). She is the John H. Ware 3rd Professor in Alzheimer's Research and directs the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Her work was instrumental in demonstrating that tau, α -synuclein and TDP-43 proteins form unique brain aggregates with a central role in numerous neurodegenerative diseases, including Alzheimer's, Parkinson's, frontotemporal dementias and amyotrophic lateral sclerosis. She is a member of the Institute of Medicine and her research on Alzheimer's disease has won her numerous awards.

Amos B. Smith, III the Rhodes-Thompson Professor of Chemistry and Member of the Monell Chemical Senses Center at the University of Pennsylvania, received the first combined B.S.-M.S degree in Chemistry at Bucknell University. After a year in Medical School (Penn), he completed his Ph.D. degree (1972) and a year as Research Associate at Rockefeller; he then joined the Department of Chemistry at Penn, serving as Chair from 1988–1996. His research interests comprise the total synthesis of natural and unnatural products, development of new synthetic methods, medicinal chemistry (AIDS and Alzheimer's diseases), peptide/peptidomimetic design and materials science. In addition, he serves as the founding Editor-in-Chief of *Organic Letters*, and is a fellow of both the American Academy of Arts and Sciences, and the American Chemical Society.




Figure 1. Schematic of the tubulin polymerization process. (A) head-to-tail polymerization of α - and β -tubulin heterodimers results in the formation of protofilaments; (B) lateral interactions between protofilaments enable them to assemble into sheets of tubulin, which fold on themselves to form hollow MT structures typically comprising 13 protofilaments per MT. (C) During MT-polymerization, guanosine-5'-triphosphate (GTP)-bound α , β -tubulin heterodimers are added at the polymerizing end of the MT. Concomitantly, or soon after incorporation into the MT, GTP-bound to β -tubulin is hydrolyzed to the corresponding diphosphate (GDP-MT). The GTP to GDP hydrolysis is not required for MT-polymerization, however, this conversion plays an important role in determining the dynamic instability of the MT, as GTP-tubulin forms more stable interactions, while GDP-tubulin establishes comparatively weaker intersubunit interactions and is, therefore, prone to depolymerization. The presence of a GTP-bound tubulin at the growing end of the MT (GTP-cap) protects the MT from depolymerization. Removal of the GTP-cap can trigger rapid depolymerization events. (D) Upon depolymerization, released tubulin heterodimers can exchange GDP with GTP and re-enter the polymerization cycle.




Figure 2. Schematic representation of the axonal transport machinery, which comprises MTs, motor proteins (kinesins and dyneins) and cargos. Kinesins and dyneins move towards the plus and the minus end of the MTs, respectively, and are involved in either the anterograde (kinesins) or retrograde (dyneins) axonal transport. The MT-stabilizing function of tau plays an important role in the organization and dynamics of axonal MTs and, as such, is critical for axonal transport. Under pathological conditions, hyperphosphorylation of tau leads to an abnormal disengagement of tau from the MTs, which results in disruption of MT-dynamics and impaired axonal transport.




Figure 3.
The structures of paclitaxel, docetaxel, 10-deacetylbaccatin III and selected examples of Pgp-insensitive taxanes.




Figure 4. Naturally occurring epothilones (A), and selected examples of synthetic epothilones (B).





Figure 5.
The structure of discodermolide and a biologically active, structurally simplified analogue (27).



(-)-Dictyostatin (28)

Figure 6.
The structure of dictyostatin.




Figure 7.
Eleutherobin, sarcodyctins and selected synthetic derivatives.






Figure 8.
Laulimalide and isolaulimalide.




R = CH₃, Peloruside A (38)
R = H, Peloruside B (39)

Figure 9.
Peloruside A and B.



(-)-Cyclostreptin (40)

Figure 10.
The structure of (-)-cyclostreptin.



	R_1	R_2
(41) Taccalonolide A	OAc	OAc
(42) Taccalonolide B	OH	OAc
(43) Taccalonolide E	OAc	H
(44) Taccalonolide N	OH	H

$R = \text{OAc}$, Taccalonolide AF (45)
 $R = \text{OH}$, Taccalonolide AJ (46)

Figure 11.
 Selected taccalonolides.




Figure 12.
The structures of naturally occurring (-)-zampanolide and (+)-dactylolide.




Figure 13.
The structures of naturally occurring ceratamine A and B, and of a synthetic congener (51).




Figure 14.
Naturally products with reported MT-stabilizing properties.




Figure 15.
MT-stabilizing GS-164, estradiol derivative **60**, and 5HPP-33.




Figure 16. Representative mono- and di-heterocyclic MT-stabilizing agents.

Table 1

Different classes of MT-stabilizing natural products and their stage of development as potential candidates for neurodegenerative tauopathies.

Compound class	Brain penetration	Stage of development in the context of tauopathies
Taxanes	Paclitaxel, docetaxel and several related analogues are not brain penetrant; selected analogues and/or prodrugs are reported to exhibit improved brain penetration. ³²⁻³⁵	Paclitaxel was evaluated in an animal model of tauopathies. ²⁵ Lack of brain penetration prevented further development of this compound.
Epothilones	Several examples reported to be brain penetrant. ³⁶⁻³⁸	Epothilone D was evaluated in animal models ^{26, 27} and recently entered Phase Ib clinical trial for AD. ²⁸
Discodermolide	Not reported	Not reported
Dictyostatin	Not reported	Not reported
Eleuthesides	Not reported	Not reported
Laulimalide	Not reported	Not reported
Peloruside	Not reported	Cell-based studies. ²¹
Cyclostreptin	Not reported	Not reported
Taccalonolides	Not reported	Not reported
Zampanolide	Not reported	Not reported
Ceratamines	Not reported	Not reported